Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Lu, Bingwen; Wu, Xiang

doi:10.4236/cm.2015.62009

Cited by 4 publications

(4 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Danshen dripping pills could be a promising method for the treatment of ischemic retinal disorders through reducing oxidative stress [6]. Our previous clinical study has demonstrated that SS injection was an effective and safe modality for treating RVO patients [7]. We also have shown that IVR injection and SS injection together could effectively improve the therapeutic effect in RVO patients with ME [8].…”

Section: Discussionmentioning

confidence: 97%

Intravitreal Ranibizumab Combined with Sulfotanshinone Sodium Injection in Treating Type II Optic Disc Vasculitis

Lu¹,

Wu²,

Zhang³

2016

CRCM

Self Cite

View full text Add to dashboard Cite

Objectives: To present the effect of intravitreal ranibizumab (IVR) therapy combined with sulfotanshinone sodium (SS) injection in a patient suffering from type II optic disc vasculitis (ODV). Methods: A 26-year-old female patient was diagnosed with type II ODV with macular edema (ME). The information was obtained by complete medical and ophthalmic history taking and a detailed ophthalmic examination at the initial and follow-up visits. Functional and morphological outcomes at baseline, 1 week and 1 month following IVR+SS injections, are presented. Results: Bestcorrected visual acuity (BCVA) improved from 78 letters (ETDRS) at baseline to 90 letters at 1-week follow-up and maintained stable through 1-month follow-up. Central retinal thickness (CRT) measured by optical coherence tomography (OCT) decreased from 465 μm at baseline to 240 μm at 1-week follow-up and to 226 μm at 1-month follow-up. Mean deviation (MD) measured by perimetry increased from −5.17 dB to −4.59 dB and to −4.29 dB, respectively. Fluorescein angiography (FFA) showed that the initial macular edema at baseline disappeared while the arm-retina circulation time (ART) was also greatly shortened when compared to the baseline. Electroretinogram (ERG) measured at 1-month follow-up demonstrated an overall improvement of the retinal function after the injection. No ocular or systemic side effects were detected. Conclusions: IVR+SS injection may lead to resolution of the associated ME and improve the retina morphologically as well as functionally. To our knowledge, this is the first case of a type II ODV benefiting from treatment with IVR+SS injection. The observed results warrant further investigation.

show abstract

Section: Discussionmentioning

confidence: 97%

Intravitreal Ranibizumab Combined with Sulfotanshinone Sodium Injection in Treating Type II Optic Disc Vasculitis

Lu¹,

Wu²,

Zhang³

2016

CRCM

Self Cite

View full text Add to dashboard Cite

show abstract

“…During the last decade, intravitreal injections of triamcinolone acetonide, bevacizumab, or ranibizumab were evolved as new major treatment modality [4]- [6]. We have also proved that SS injection could effectively improve the therapeutic effect in patients with non-ischemic RVO [7]. In order to observe the therapeutic effect of the treatment on RVO patients and specify conditions for retreatment in their follow-up, evaluation of the macular function is of paramount meaning.…”

Section: Discussionmentioning

confidence: 99%

“…But recently, an increasing number of reports have shown the efficacy of new methods on ME resulting from RVO, such as intravitreal injections of triamcinolone acetonide, bevacizumab, or ranibizumab [4]- [6]. Our previous study has also demonstrated that sulfotanshinone sodium (SS) injection could effectively improve the therapeutic effect in patients with non-ischemic RVO [7].…”

Section: Introductionmentioning

confidence: 99%

Retinal Functional Changes Measured by Microperimetry after Intravitreal Ranibizumab Injection and Sulfotanshinone Sodium Injection for Macular Edema Secondary to Retinal Vein Occlusion

Lu¹,

Wu²

2015

Self Cite

View full text Add to dashboard Cite

Objectives: To study the visual field changes after intravitreal ranibizumab (IVR) injection and sulfotanshinone sodium (SS) injection for macular edema (ME) secondary to retinal vein occlusion (RVO), and discuss the value of microperimetry as a routine diagnostic test in the follow-up of RVO patients. Methods: This was a retrospective, interventional, case-series study. Twelve eyes of 12 RVO patients, including 6 eyes with central RVO (CRVO) and 6 eyes with branch RVO (BRVO) were included. The eyes were treated with IVR (0.5 mg) injections and SS injections (20 mg per day, one week consecutively in one month). The outcomes measured included best corrected visual acuity (BCVA), central retinal thickness (CRT), mean defect (MD), pattern standard deviation (PSD), macular light sensitivity of the central 16 points in CRVO group and the central 8 points in BRVO group before and after the treatment. Statistical analyses were then performed on the main outcome measures. Results: An improvement of BCVA was found in all patients after treatment with significant difference (t = 7.74, p < 0.01). CRT improved from (700.3 ± 184.9) μm before treatment to (235.3 ± 36.5 μm) after treatment (t = 8.24, p < 0.01). As for the results of visual field, MD improved significantly (t = 5.83, p < 0.01), whereas the changes of PSD showed no significant importance (t = 2.17, p > 0.05). All RVO patients had their macular light sensitivity of the involved part improved significantly (t = 5.03, p < 0.01). Both the macular light sensitivity of the central 16 points in the CRVO group and the macular light sensitivity of the central 8 points in the BRVO group improved with statistical importance (t = 3.78, p < 0.05; t = 5.38, p < 0.01). The Pearson's correlation was calculated among BCVA, MD, macular light sensitivity and CRT. No obvious significance was found between CRT and BCVA outcomes, whereas MD and mean macular light sensitivity outcomes were closely related to BCVA results in the BRVO group and the latter showed a B. W. Lu, X. W. Wu 182 more intimate correlation. No similar correlation was found in RVO and CRVO group. Conclusion: IVR injection and SS injection together could effectively improve the therapeutic effect in RVO patients with ME. Microperimetry could be used as a routine diagnostic test and a possible valuable tool in the follow-up of patients with RVO, especially in BRVO.

show abstract

“…Our previous studies have shown that combined treatment of traditional Chinese and Western method could have certain advantages[10] [11]. LQHB is a compound Chinese herbal medicine of Shanghai General Hospital (Shanghai medicine system of…”

mentioning

confidence: 99%

Clinical Study of “Lingqi Huangban Granule” in Treating Choroidal Neovascularisation in Pathologic Myopia

Lu¹,

Wu²,

Zhang³

2016

Self Cite

View full text Add to dashboard Cite

Objectives: To study the therapeutic effects of "Lingqi Huangban Granule" (LQHB) combined with intravitreal ranibizumab injection (IVR) for choroidal neovascularisation (CNV) in pathologic myopia (PM). Methods: This was a prospective, comparative, interventional study. Eighty eyes of eighty consecutive patients with myopic CNV were randomized into control group (IVR, 40 eyes) and integrative therapy group (IVR + LQHB, 40 eyes), each with a follow-up period of 12 months. IVR was given with an "on demand" regimen (Pro re nata, PRN). Final best corrected visual acuity (BCVA) and its change from baseline were the main outcome measures. Changes in optical coherence tomography (OCT) and central retinal thickness (CRT) were the secondary outcome measures. Results: BCVA of patients in the integrative group improved significantly (from 47.10 ± 13.51 letters to 90.72 ± 12.98 letter, P < 0.05), more than in the control group (from 42.90 ± 13.18 letters to 69.18 ±13.21 letters, P < 0.05) since the third month after the initial treatment to the end of the follow-up. Mean OCT CRT reduced from 364.75 ± 69.31 to 278.93 ± 33.05 um (P < 0.05) in the control group and from 370.73 ± 65.31 to 271.73 ± 46.44 um (P < 0.05) in the integrative group, respectively. The mean number of intravitreal injections in the 1-year follow-up was also reduced. No ocular or systemic side effects were observed. Conclusion: LQHB combined with IVR therapy was an effective treatment for stabilizing and improving vision with fewer intravitreal injections. It appears to be an interesting option for this type of patient.

show abstract

Clinical Study of Sulfotanshinone Sodium Injection in Treating Non-Ischemic Retinal Vein Occlusion

Cited by 4 publications

References 13 publications

Intravitreal Ranibizumab Combined with Sulfotanshinone Sodium Injection in Treating Type II Optic Disc Vasculitis

Intravitreal Ranibizumab Combined with Sulfotanshinone Sodium Injection in Treating Type II Optic Disc Vasculitis

Retinal Functional Changes Measured by Microperimetry after Intravitreal Ranibizumab Injection and Sulfotanshinone Sodium Injection for Macular Edema Secondary to Retinal Vein Occlusion

Clinical Study of “Lingqi Huangban Granule” in Treating Choroidal Neovascularisation in Pathologic Myopia

Contact Info

Product

Resources

About